A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Pfizer
Merck Sharp & Dohme LLC
Compass Therapeutics
Revolution Medicines, Inc.
Pfizer
Seagen Inc.
GlaxoSmithKline
Elicio Therapeutics
Medtronic - MITG
Delcath Systems Inc.
Pfizer
Accent Therapeutics
Averto Medical, Inc.
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
GlaxoSmithKline
Natera, Inc.
GlaxoSmithKline
Immunophotonics, Inc.
Novartis
Var2 Pharmaceuticals
Freenome Holdings Inc.
Novartis
GlaxoSmithKline
Massive Bio, Inc.
Colospan Ltd.
Chongqing Precision Biotech Co., Ltd
First Ascent Biomedical Inc.
A2 Biotherapeutics Inc.
Elicio Therapeutics
Guardant Health, Inc.
Pfizer
SafeHeal Inc
ModeX Therapeutics, An OPKO Health Company
Medicine Invention Design, Inc
Shanghai Cingularbio Co. Ltd
Tempus AI
Qufora A/S
GILongevity
Mirati Therapeutics Inc.
Amal Therapeutics
Viome
Taproot Health
ADVANCED MARKER DISCOVERY S.L.
Hutchmed
Gene Solutions
Chongqing Precision Biotech Co., Ltd
NantBioScience, Inc.